Results 21 to 30 of about 1,494 (190)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) — diagnostic and therapeutic challenge [PDF]

Hematology in Clinical Practice, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive haematological malignancy. The disease usually affects the skin, bone marrow, peripheral blood and less commonly lymph nodes. The actual incidence of BPDCN is currently unknown.
Jarosław Wajs, Małgorzata Lewandowska, Przemysław Kluge, Lucyna Drążek, Dorota Jesionek-Kupnicka   +4 more
openaire   +2 more sources

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity

eJHaem, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these
Margaux Poussard, Laure Philippe, Maxime Fredon, Elodie Bôle‐Richard, Sabeha Biichle, Florian Renosi, Sophie Perrin, Marie Kroemer, Samuel Limat, Francis Bonnefoy, Etienne Daguindau, Eric Deconinck, Bérengère Gruson, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre   +16 more
doaj   +2 more sources

Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) [PDF]

Bone Marrow Transplantation, 2021
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT). We report on all 17 patients with BPDCN who underwent allo-HCT at our center between 2000 and 2020. The median age was 39 (18-67) years.
Qaiser Bashir, Denái R. Milton, Uday R. Popat, Partow Kebriaei, Chitra Hosing, Issa F. Khouri, Katayoun Rezvani, Yago Nieto, Betul Oran, Samer A. Srour, Neeraj Y. Saini, Amanda L. Olson, Sairah Ahmed, Gheath Al-Atrash, Gabriela Rondon, Marina Y. Konopleva, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Naveen Pemmaraju   +19 more
openaire   +3 more sources

Case Report: Tumor-related hemorrhage determined treatment sequencing in blastic plasmacytoid dendritic cell neoplasm coexisting with gastric cardia adenocarcinoma [PDF]

Frontiers in Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy that commonly presents with skin involvement and may also involve the bone marrow, peripheral blood, and lymph nodes.
Yuze Li, Chenggong Zhang, Xudong Song, Guoquan Tao   +3 more
doaj   +2 more sources

BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid–dendritic cell leukemia [PDF]

JCI Insight
MYB fusions are recurrently found in select cancers, including blastic plasmacytoid DC neoplasm (BPDCN), an acute leukemia with poor prognosis. They are markedly enriched in BPDCN compared with other blood cancers and, in some patients, are the only ...
Christopher A.G. Booth, Juliette M. Bouyssou, Katsuhiro Togami, Olivier Armand, Hembly G. Rivas, Kezhi Yan, Siobhan Rice, Shuyuan Cheng, Emily M. Lachtara, Jean-Pierre Bourquin, Alex Kentsis, Esther Rheinbay, James A. DeCaprio, Andrew A. Lane   +13 more
doaj   +2 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Rash

Journal of Community Hospital Internal Medicine Perspectives, 2023
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic malignancy derived from type 2 Dendritic cells (immature Plasmacytoid dendritic cells). It is an aggressive lymphoma and most commonly presents as nonpruritic cutaneous lesions. It can also involve the bone marrow, lymph nodes, or circulating peripheral blasts. Here we present a
Al-Alwan, Ahmad, Khalid, Farhan, Vyas, Charmee, Sirpal, Vishakha, Bader, Husam   +4 more
openaire   +3 more sources

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation. [PDF]

EJHaem
ABSTRACT Introduction Acute myeloid leukemia (AML) with plasmacytoid dendritic cell differentiation (pDC‐AML) is a newly described subtype of leukemia with features resembling blastic plasmacytoid dendritic cell neoplasm (BPDCN). Case Presentation Herein, we present a case of pDC‐AML in which bone marrow findings were best classified as AML, whereas ...
Lee BJ, Griffin SP, Jeyakumar D, Gamayo A, Rezk SA, Naqvi K.   +5 more
europepmc   +2 more sources

Petechiae and a Persistent Violaceous Nodule: A Presentation of Blastic Plasmacytoid Dendritic Cell Neoplasm to Dermatology

Case Reports in Dermatological Medicine
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive CD4+ CD56+ hematopoietic malignancy. The cutaneous presentation is variable but often includes violaceous nodules.
Madison Anzelc, Christina Druskovich, Austin Cusick, Matthew Franklin   +3 more
doaj   +2 more sources

Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis [PDF]

Frontiers in Oncology
BackgroundTagraxofusp is a first-in-class CD123-targeted therapy approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Although venetoclax is not approved for BPDCN, limited use has been reported.
Anthony S. Stein, Guru Subramanian Guru Murthy, Pankit Vachhani, Sunil Iyer, Deborah Goldschmidt, Yipeng Gao, John Katsetos, Corey Pelletier, Tibor Kovacsovics   +8 more
doaj   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review [PDF]

Frontiers in Immunology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. Recent studies have highlighted its occurrence in patients with a history of preceding myeloid neoplasms.
Yao Sun, Yingjie Liu, Na Liu, Xiaohui Zhang, Wenrong Huang, Liangding Hu   +5 more
doaj   +2 more sources